Autoimmune Encephalitis
Conditions
Interventions
Control:Routine first-line immunotherapy
test group:mycophenolate mofetil
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Aged 18-80 years, male or female. (2) one or more of the 8 core clinical manifestations: mental disorders, memory loss, language disorders, seizures, motor disorders, disturbance of consciousness, autonomic nerve dysfunction or central hypoventilation; (3) autoimmune encephalitis antibodies detected in cerebrospinal fluid [CBA method: (anti-NMDARGABAB-R and LGI1/CASPR2 antibody)]. (4) reasonable exclusion of other diseases. (5) AIE relapse for one time or more.
Exclusion criteria
Exclusion criteria: (1) Patients with (HIV) infection of human immunodeficiency virus, brain abscess, viral disease, brain malaria, brain tumor or non-communicable central nervous system disease (such as acute demyelinating encephalomyelitis (ADEM); (2) patients with central nervous system infection of viruses, bacteria, fungi, parasites or Mycobacterium tuberculosis (TB). (3) Encephalopathy secondary to septicemia or systemic inflammatory response syndrome; (4) patients diagnosed with epilepsy, brain trauma and/or other neurological diseases before the onset of encephalitis. (5) other autoimmune encephalitis patients with positive serum and/or CSF laboratory tests: a-amino 3-hydroxy-5-hydroxy-5-methyl-4-isoxazolyl-propionate (AMPA) receptor antibody encephalitis, glutamic acid decarboxylase (GAD) antibody encephalitis; (6) patients lacking key clinical data; (7) pregnant or breastfeeding patients. (8) patients with contraindications using MMF, such as severe infection, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cognitive function and inflammatory factor; | — |
Countries
China
Contacts
Public ContactZhen Hong
West China Hospital, Sichuan University
Outcome results
None listed